山德士Sandoz 2023年综合年度报告「瑞士证券交易所」（英文版）（250页）.pdf

1、Integrated Annual Report 2023Pioneering access for patientsOur Vision is to be the worlds leading and most valued biosimilars and generics company.Read more/Page 07Pioneering access for patients.Our PurposeOur Vision01OverviewOverview02 Sandoz in six letters04 Chairmans letter06 Chief Executives sta

2、tement08 Our investment case10 Our strategy12 Our year in reviewCorporate Report14 Scientific heritage20 Access is our purpose32 Novel ways drive performance44 Democratizing biologics50 Optimizing our presence58 Zeroing in on ESGGovernance,Compensation and Risk70 Corporate Governance 91 Compensation

3、 Report114 Risk managementFinancial Report123 Performance overview128 Financial statements 201 Supplementary financial informationESG Additional Disclosures221 ESG reporting compliance index222 Additional information on ESG KPIs226 Materiality assessment and methodology228 ESG performance:KPIs and d

4、ata235 SASB and GRI reporting index244 Assurance statementWhats inside2023 financial highlights12023 non-financial highlights2NET SALES TO THIRDPARTIES9.6USD billion,7%growth in constant currenciesCORE EBITDA MARGIN18.1%Core EBITDA of USD 1.7billionCORE NET INCOME953USD millionPATIENT TREATMENTS 800

5、Estimated number of patient treatments provided in millionsSAVINGS DELIVERED TO US AND EU HEALTHCARE SYSTEMS18Estimate in USD billion delivered by our key productsSOCIAL IMPACT 400Estimate in USD billion delivered by our key products1 Non-IFRS measures as defined by Sandoz can be found in the sectio

6、n Supplementary financial information.2 Non-financial indicators definitions can be found on our website: Annual Report 2023Graphics inspired by the“Swiss style”The Sandoz visual identity comprises a set of interconnected elements,from logo and colors to photography style and new illustrations,as we